Effects of re-challenge with temozolomide in grade 2/3 IDH mutant gliomas at first progression
These findings suggest previously treated, progressive IDHmt gliomas are generally resistant to TMZ, underscoring the need for alternative approaches.
Authors
- Zachary Scharf
- James T. Patrie (ORCID: https://orcid.org/0000-0001-7392-830X)
- David Schiff
- Lalanthica V. Yogendran
- Salma Abbas (ORCID: https://orcid.org/0009-0005-2679-0471)
- Sohil H. Patel (ORCID: https://orcid.org/0000-0002-9739-4362)
- Abhinav Kareddy
Institutions
- Engineering Systems (United States) (US)
- University of Virginia (US)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Journal of Neuro-Oncology
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1007/s11060-025-05087-w
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63